Cargando…

Nevirapine Resistance and Breast-Milk HIV Transmission: Effects of Single and Extended-Dose Nevirapine Prophylaxis in Subtype C HIV-Infected Infants

BACKGROUND: Daily nevirapine (NVP) prophylaxis to HIV-exposed infants significantly reduces breast-milk HIV transmission. We assessed NVP-resistance in Indian infants enrolled in the “six-week extended-dose nevirapine” (SWEN) trial who received single-dose NVP (SD-NVP) or SWEN for prevention of brea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moorthy, Anitha, Gupta, Amita, Bhosale, Ramesh, Tripathy, Srikanth, Sastry, Jayagowri, Kulkarni, Smita, Thakar, Madhuri, Bharadwaj, Renu, Kagal, Anju, Bhore, Arvind V., Patil, Sandesh, Kulkarni, Vandana, Venkataramani, Varadharajan, Balasubramaniam, Usha, Suryavanshi, Nishi, Ziemniak, Carrie, Gupte, Nikhil, Bollinger, Robert, Persaud, Deborah
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2606064/ https://www.ncbi.nlm.nih.gov/pubmed/19119321 http://dx.doi.org/10.1371/journal.pone.0004096

Ejemplares similares

Growth patterns among HIV-exposed infants receiving nevirapine prophylaxis in Pune, India
por: Ram, Malathi, et al.
Publicado: (2012)

Efficacy of Six-Week Extended-Dose Nevirapine Varies by Infant Birth Weight with Greatest Relative Efficacy in Low Birth Weight Infants
por: Gupte, Nikhil, et al.
Publicado: (2016)

Twelfth-Position Deuteration of Nevirapine Reduces 12-Hydroxy-Nevirapine Formation and Nevirapine-Induced Hepatocyte Death
por: Heck, Carley J. S., et al.
Publicado: (2020)

Nevirapine induced exfoliative dermatitis in an HIV-infected patient
por: Bhandarkar, Anoosha P., et al.
Publicado: (2011)

Solid State Characterization and Dissolution Enhancement of Nevirapine Cocrystals
por: Panzade, Prabhakar, et al.
Publicado: (2021)

High Rates of All-cause and Gastroenteritis-related Hospitalization Morbidity and Mortality among HIV-exposed Indian Infants
por: Singh, Harjot K, et al.
Publicado: (2011)

Nevirapine induced Stevens–Johnson syndrome in an HIV infected patient
por: Singh, Harminder, et al.
Publicado: (2011)

2'-Deoxythymidine Adducts from the Anti-HIV Drug Nevirapine
por: Antunes, Alexandra M. M., et al.
Publicado: (2013)

Adverse Events in a Cohort of HIV Infected Pregnant and Non-Pregnant Women Treated with Nevirapine versus Non-Nevirapine Antiretroviral Medication
por: Aaron, Erika, et al.
Publicado: (2010)

Clonal amplification and maternal-infant transmission of nevirapine-resistant HIV-1 variants in breast milk following single-dose nevirapine prophylaxis
por: Permar, Sallie R, et al.
Publicado: (2013)

Incidence and Determinants of Nevirapine and Efavirenz-Related Skin Rashes in West Africans: Nevirapine's Epitaph?
por: Sarfo, Fred Stephen, et al.
Publicado: (2014)

Solid-State Characterization of Nevirapine
por: Sarkar, Mahua, et al.
Publicado: (2008)

Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children
por: Gonzalez-Tome, M Isabel, et al.
Publicado: (2008)

Co-administration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans
por: Wakeham, Katie, et al.
Publicado: (2010)

Covalent Histone Modification by an Electrophilic Derivative of the Anti-HIV Drug Nevirapine
por: Harjivan, Shrika G., et al.
Publicado: (2021)

Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole
por: Manosuthi, Weerawat, et al.
Publicado: (2007)

Association of Nevirapine Levels with Rash or Hepatotoxicity Among HIV-Infected Thai Women
por: Ratanasuwan, Winai, et al.
Publicado: (2012)

Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship
por: Bhatt, Nilesh B., et al.
Publicado: (2015)

Nevirapine-induced Stevens-Johnson syndrome in children living with HIV in South Africa
por: du Toit, Jacques D., et al.
Publicado: (2021)

Preparation and Characterisation of Nevirapine Oral Nanosuspensions
por: Raju, Anju, et al.
Publicado: (2014)

Maternal Syphilis: An Independent Risk Factor for Mother to Infant Human Immunodeficiency Virus Transmission
por: Kinikar, Aarti, et al.
Publicado: (2017)

HLA involvement in nevirapine-induced dermatological reaction in antiretroviral-treated HIV-1 patients
por: Umapathy, Shankarkumar, et al.
Publicado: (2011)

HIV-1 reverse transcriptase complex with DNA and nevirapine reveals nonnucleoside inhibition mechanism
por: Das, Kalyan, et al.
Publicado: (2012)

Nevirapine Plasma Concentrations Are Associated with Virologic Response and Hepatotoxicity in Chinese Patients with HIV Infection
por: Wang, Jia, et al.
Publicado: (2011)

Genome-wide association study of nevirapine hypersensitivity in a malawian HIV-infected population
por: Carr, Daniel, et al.
Publicado: (2014)

Cutaneous drug-reactions to nevirapine: study of risk factors in 268 HIV-infected patients
por: Badaoui, L, et al.
Publicado: (2014)

Intrinsic Replication Competences of HIV Strains After Zidovudine/Lamivudine/Nevirapine Treatment in the Philippines
por: Kageyama, Seiji, et al.
Publicado: (2019)

Development of a liposomal nanodelivery system for nevirapine
por: Ramana, Lakshmi N, et al.
Publicado: (2010)

DRESS Syndrome due to Nevirapine Treated with Methylprednisolone
por: Pott Junior, Henrique, et al.
Publicado: (2013)

Antioxidant modulation of nevirapine induced hepatotoxicity in rats
por: Awodele, Olufunsho, et al.
Publicado: (2015)

48-week efficacy and safety of transitioning virologically stable HIV-1 patients from nevirapine IR 200 mg BID to nevirapine XR 400 mg QD (TRANxITION)
por: Arastéh, K, et al.
Publicado: (2010)

Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi
por: Dickinson, L, et al.
Publicado: (2010)

Nevirapine-Based Antiretroviral Therapy Impacts Artesunate and Dihydroartemisinin Disposition in HIV-Infected Nigerian Adults
por: Fehintola, Fatai A., et al.
Publicado: (2012)

Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals
por: Schipani, Alessandro, et al.
Publicado: (2011)

Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults
por: Byakika-Kibwika, Pauline, et al.
Publicado: (2012)

HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients
por: Likanonsakul, Sirirat, et al.
Publicado: (2009)

Association of Human Leukocyte Antigen Alleles and Nevirapine Hypersensitivity in a Malawian HIV-Infected Population
por: Carr, Daniel F., et al.
Publicado: (2013)

Population Pharmacokinetic and Pharmacogenetic Analysis of Nevirapine in Hypersensitive and Tolerant HIV-Infected Patients from Malawi
por: Dickinson, Laura, et al.
Publicado: (2014)

Efficacy and safety of switching from nevirapine immediate-release twice daily to nevirapine extended-release once daily in virologically suppressed HIV-infected patients: a retrospective cohort study in Taiwan
por: Lee, Chun-Yuan, et al.
Publicado: (2017)

High risk for occupational exposure to HIV and utilization of post-exposure prophylaxis in a teaching hospital in Pune, India
por: Gupta, Amita, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_l6sqe29b4bun0vbft3r382kucb